Stocks and Investing Stocks and Investing
Thu, September 16, 2021
Wed, September 15, 2021

Whitney Ijem Upgraded (SRPT) to Strong Buy on, Sep 15th, 2021


Published on 2024-10-27 17:55:20 - WOPRAI, Whitney Ijem
  Print publication without navigation


Whitney Ijem of Guggenheim, Upgraded "Sarepta Therapeutics, Inc." (SRPT) to Strong Buy on, Sep 15th, 2021.

Whitney has made no other calls on SRPT in the last 4 months.



There are 5 other peers that have a rating on SRPT. Out of the 5 peers that are also analyzing SRPT, 3 agree with Whitney's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Decreased Target to $90 on, Monday, August 16th, 2021
  • Anupam Rama of "JP Morgan" Upgraded from Sell to Hold and Decreased Target to $87 on, Thursday, August 5th, 2021
  • Judah Frommer of "Credit Suisse" Maintained at Hold with Increased Target to $75 on, Thursday, August 5th, 2021


These are the ratings of the 2 analyists that currently disagree with Whitney


  • Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy with Decreased Target to $122 on, Thursday, August 5th, 2021
  • Yun Zhong of "BTIG" Initiated at Strong Buy and Held Target at $110 on, Tuesday, June 15th, 2021

Contributing Sources